These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20946268)

  • 1. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
    Cai B; Katz L; Alexander CM; Williams-Herman D; Girman CJ
    Int J Clin Pract; 2010 Nov; 64(12):1601-8. PubMed ID: 20946268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database.
    Brodovicz KG; Kou TD; Alexander CM; O'Neill EA; Senderak M; Engel SS; Girman CJ
    Int J Clin Pract; 2013 May; 67(5):449-54. PubMed ID: 23574104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
    Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
    Mohan V; Yang W; Son HY; Xu L; Noble L; Langdon RB; Amatruda JM; Stein PP; Kaufman KD
    Diabetes Res Clin Pract; 2009 Jan; 83(1):106-16. PubMed ID: 19097665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incretin enhancer: sitagliptin].
    Kondo M; Tanizawa Y
    Nihon Rinsho; 2011 May; 69(5):859-63. PubMed ID: 21595272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
    BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
    Perusicová J
    Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation.
    White PC; Chamberlain-Shea H; de la Morena MT
    J Diabetes Complications; 2010; 24(3):209-13. PubMed ID: 19854074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
    Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
    Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
    Scott R; Wu M; Sanchez M; Stein P
    Int J Clin Pract; 2007 Jan; 61(1):171-80. PubMed ID: 17156104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
    Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.